Revvity, Inc. (NYSE: RVTY) has announced robust financial results for the first quarter of 2026, surpassing market expectations with revenue of $711 million and adjusted earnings per share (EPS) of $1.06. The company reported a 3% total organic growth rate, with its Life Sciences segment showing particular resilience as pharmaceutical and biotech spending begins to stabilize.

For lab managers, the quarter marks a significant strategic pivot as the company seeks to distance itself from lower-margin diagnostic markets to focus on advanced discovery and automation technologies.

Life sciences discovery and automation rebound

A standout theme in the Q1 earnings call was the return of pharma and biotech spending. Revvity reported low double-digit year-over-year organic growth from these customers—the strongest performance in this segment since early 2023.

"Our results reflect the successful execution of our strategic initiatives and a commitment to innovation," said Prahlad Singh, President and CEO of Revvity.

Key takeaways for research and discovery labs include:

• Academic recovery: For the first time since Q2 2023, the company saw positive growth from academic and government customers in the U.S., signaling a potential easing of the budget constraints that have recently hampered other suppliers like Bio-Rad.
• Instrument demand: Unlike the broader "instrument softness" reported by peers, Revvity noted a modestly improved environment for both reagents and instrument sales in the discovery space.
• Bioprocessing and discovery: This mirrors broader industry reports of a turning point in recovery and transformation across the life sciences sector.

Strategic divestiture of China immunodiagnostics

The most significant operational update was the planned divestiture of Revvity’s immunodiagnostics business in China. This business, which represented 6% of total revenue last year, has faced persistent policy-induced pricing pressures and regulatory headwinds.

"The healthcare market in China, particularly diagnostics, has faced persistent policy-induced headwinds that have dramatically impacted both customer demand and pricing dynamics," explained Prahlad Singh. "Rather than deploying material dollars and management attention to address these structural challenges... we are choosing to concentrate our efforts on business areas where we have clear competitive advantages."

By exiting this lower-margin space, Revvity aims to:

• Focus on high-growth areas: Pro forma organic growth for the quarter (excluding this business) would have been 6%, rather than 3%.
• Leverage Life Science strength in China: Interestingly, Revvity’s life sciences business in China—which is larger than the diagnostics unit being sold—continues to grow "solidly above" overall reagent performance.
• Improve cash flow: CFO Max Krakowiak noted that excluding this business would have improved the company's free cash flow conversion by approximately 300 basis points in 2025.

Innovation in software and AI-first workflows

Revvity is aggressively expanding its "Signals" software ecosystem, targeting labs that require advanced computational capabilities alongside traditional research.

• Xynthetica and BioDesign: The company recently introduced Xynthetica, an AI-models-as-a-service platform, and BioDesign, a cloud-native molecular design platform for biologics. Singh noted that BioDesign is currently the "only cloud-based offering of its type" for molecular biology teams developing antibody and cell therapies.
• LabGistics: Scheduled for launch later this year, LabGistics will be an "AI-first" drug discovery-to-development workflow offering. This shift toward "dry lab" computational tools is becoming a key differentiator in lab procurement as managers seek to maximize data utility.

Procurement and operations briefing: Insights for lab managers

For lab managers evaluating Revvity as a partner in 2026, the Q1 results suggest several strategic considerations:

1. Automation and Software Integration. Revvity's focus on cloud-native and AI-first software suggests that labs invested in their ecosystem may see faster integration between hardware and data analysis. The goal is a "seamless marketplace connecting computational capabilities to wet lab research," specifically targeting cell and gene therapy applications.

2. Shift Toward Discovery Excellence. With the divestiture of its high-volume diagnostics business in China, Revvity is signaling that it will prioritize innovation in high-end discovery instruments and reagents. Lab managers should view this as a commitment to higher-value discovery tools, similar to the strategic microbiology sell-offs seen recently from Thermo Fisher.

Lab Management Certificate

The Lab Management certificate is more than training—it’s a professional advantage.

Gain critical skills and IACET-approved CEUs that make a measurable difference.

3. Budget Cycle Awareness and Reproductive Health. While pharma spending is improving, management noted that customer behavior remains "measured." However, certain segments like Reproductive Health grew in low double digits, driven by success in newborn screening and a major contract with Genomics England. Managers in these specialized sectors may find Revvity prioritizing supply and support for these high-performing units.

4. Portfolio Simplification. Revvity has updated its full-year 2026 pro forma guidance to reflect the divestiture, now expecting total revenue of $2.81 billion to $2.84 billion. As the company continues to refine its portfolio, lab managers should expect a more streamlined partner focused on the intersection of advanced biology and computational intelligence.